Author archives: Zacks Equity Research

GFI vs. FNV: Which Stock Is the Better Value Option?

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors’ attention when BHC reports Q4 results.

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

Led by a robust performance across segments, AutoNation (AN) reports an earnings beat in fourth-quarter of 2021.

NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.

Arch Capital (ACGL) stock soars on the back of improved underwriting income, growth in Australia’s single-premium mortgage insurance and strategic acquisitions.

Higher contribution from the Electric Power Infrastructure Services unit is likely to aid Quanta Services’ (PWR) Q4 results.

AON’s new share buyback authorization brings the total available fund for share repurchase to $9.2 billion.

Investor focus is likely to be on the progress of Moderna’s (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.

Entergy’s (ETR) Q4 results are expected to reflect mixed weather pattern impacts along with the effect of higher operating expenses.